Assessing Lesion Types With MS Biomarkers
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, discuss how use of biomarkers has affected understanding and assessment of lesion types.
EP: 1.The Value of Biomarker in Multiple Sclerosis
EP: 2.Evolving Methods of Multiple Sclerosis Diagnosis
EP: 3.Assays to Detect Neurofilament Light
EP: 4.Challenges and Opportunity With MRI
EP: 5.Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions
EP: 6.Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care
EP: 7.Practical Considerations for the Use of Neurofilament Light Chain and MRI
EP: 8.How to Address Increasing Neurofilament Light Chain Levels
EP: 9.Weighing Treatment Decisions Based on Neurofilament Light Chain Levels
EP: 10.Monitoring Patients After a Change in Treatment Regimen
EP: 11.Assessing Lesion Types With MS Biomarkers
EP: 12.Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease
EP: 13.The CLIMB Study
EP: 14.Reimbursement for MRI
EP: 15.Understanding the Underlying Progression of Multiple Sclerosis
EP: 16.Biomarkers, Patient Communication, and the Future of Care
EP: 17.Question and Answer about Neurofilament Light Chain and Other MS Biomarkers
In this part of the conversation, Mark Freedman, MD, MSc, discusses the data showing that gadolinium-enhancing lesions are often the ones that heal and exhibit remyelination. He challenges the assumption that every enhancing lesion is necessarily bad and highlights the complexity of interpreting such lesions.
Tanuja Chitnis, MD, acknowledges the potential reparative potential of some cells moving into the brain with gadolinium-enhancing lesions. However, she emphasizes the general goal of reducing gadolinium-enhancing lesions, and the variability in axonal damage and lesion types between individuals. Experts further underscore the limitations of markers like NFL and the potential inaccuracies associated with individual cases.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
